Safety and Effectiveness of D-serine in Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Schizophrenia
Interventions
DRUG

D-serine

D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.

DRUG

D-serine

DRUG

D-serine

DRUG

D-serine

Trial Locations (3)

10962

The Nathan S. Kline Institute for Psychiatric Research, Orangeburg

11004

The Zucker Hillside Hospital, Glen Oaks

06512

Yale University School of Medicine, New Haven

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Nathan Kline Institute for Psychiatric Research

OTHER

NCT00322023 - Safety and Effectiveness of D-serine in Schizophrenia | Biotech Hunter | Biotech Hunter